Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753778 | 0.92 | KDM1A (0.38) | KDM1ACTSLCHRM1 | |
| SCHEMBL6749624 | 0.88 | F10 (0.43) | HPGDSSIRT2SIRT1SIRT3 | |
| SCHEMBL6747834 | 0.86 | HPGDS (0.44) | CTSVCTSLCTSBCTSSRAB9A | |
| SCHEMBL6751670 | 0.85 | KDM1A (0.40) | KDM1ACTSLCTSBCTSSPDE2A | |
| SCHEMBL6749630 | 0.85 | HPGDS (0.39) | CTSVCTSLCTSBCTSSNPC1 | |
| SCHEMBL6985444 | 0.84 | HPGDS (0.39) | CTSVCTSLCTSBCTSSRAB9A | |
| SCHEMBL6751642 | 0.84 | CTSL (0.45) | CTSVCTSLCTSBCTSSRAB9A | |
| SCHEMBL6752290 | 0.84 | CTSL (0.46) | CTSLNPC1RAB9AHPGDSLMNA | |
| SCHEMBL6752292 | 0.82 | HPGDS (0.37) | CTSLRAB9AHPGDSLMNA | |
| SCHEMBL6747703 | 0.81 | CTSL (0.40) | CTSVCTSLCTSBCTSSHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | KDM1A 1902/4885CTSV 32/4885CTSL 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.